AMLX

#1890
Amylyx Pharmaceuticals, Inc. Common Stock
15.17
+1.68%
Сектор:
Базовая:
Валюта прибыли:
Дневной диапазон
15.17
15.17
Годовой диапазон
2.60
17.49
Дневное изменение
+1.68%
Месячное изменение
-2.00%
6-месячное изменение
+60.53%
Годовое изменение
+384.66%
Предыдущее закрытие
14.92
Open
15.17
Bid
Ask
Low
15.17
High
15.17
Объем
174
Open full chart

Financials

Overview Отчетность Statistics Dividends
Quarterly Annual
Income statement Balance sheet Cash flow
Value 202220232024 TTM

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

Новости